Investigating safety, tolerability and pharmakinetics when giving single and fractionated doses of AZD3241 to healthy volunteers - SAD
Study identifier:D0490C00012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Single-centre, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD3241 following Administration of Single Ascending (Part A) and Fractionated Ascending (Part B) Oral Doses to Young Healthy Volunteers
Medical condition
Healthy Volunteers
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD3241, Placebo
Sex
All
Actual Enrollment
64
Study type
Interventional
Age
18 Years - 49 Years
Date
Study Start Date: 01 Jul 2008
Primary Completion Date: 01 Nov 2008
Study Completion Date: 01 Nov 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2008 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD3241 single oral dose |
| Placebo Comparator: 2 | - |
Contacts
Investigators
Principal Investigator
Ingemar Bylesjö
Astrazeneca Clinical Pharmacology Unit, Stockholm, Sweden
